Who makes Crizotinib Oral Capsule [Xalkori]?

Crizotinib Oral Capsule [Xalkori] is developed by Pfizer Inc..

What development phase is Crizotinib Oral Capsule [Xalkori] in?

Crizotinib Oral Capsule [Xalkori] is in Phase 2.

What are the side effects of Crizotinib Oral Capsule [Xalkori]?

Common side effects include Nausea, Diarrhoea, Vomiting, Constipation, Alanine aminotransferase increased, Aspartate aminotransferase increased.

What is the generic name of Crizotinib Oral Capsule [Xalkori]?

crizotinib-oral-capsule-xalkori is the generic (nonproprietary) name of Crizotinib Oral Capsule [Xalkori].

Last reviewed 2026-04-20 · How we verify

Crizotinib Oral Capsule [Xalkori] (crizotinib-oral-capsule-xalkori)

Pfizer Inc. · Phase 2 active Quality 15/100

At a glance

Generic name	crizotinib-oral-capsule-xalkori
Sponsor	Pfizer Inc.
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

Nausea
Diarrhoea
Vomiting
Constipation
Alanine aminotransferase increased
Aspartate aminotransferase increased
Photopsia
Dysgeusia
Decreased appetite
Blood creatinine increased
Hepatic function abnormal
Visual impairment

Key clinical trials

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases (PHASE3)
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer (PHASE3)
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC (PHASE3)
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (PHASE2)
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (PHASE3)
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (PHASE3)
Safety and Efficacy of Xalkori ROS1

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Crizotinib Oral Capsule [Xalkori] CI brief — competitive landscape report
Crizotinib Oral Capsule [Xalkori] updates RSS · CI watch RSS
Pfizer Inc. portfolio CI